This study evaluated the in vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent, geographically diverse, Pseudomonas aeruginosa isolates from a global surveillance program as well as molecularly characterized extended-spectrum-β-lactamase-positive, metallo-β-lactamase-positive, and colistin-resistant strains. KHP-3757 (MIC_50/90, 0.25/0.5 mg/L; 97.4% inhibited at ≤0.5 mg/L) demonstrated potent in vitro activity based on MIC₉₀ values against P. aeruginosa isolates including extended-spectrum-β-lactamase-positive, metallo-β-lactamase-positive, and colistin-resistant strains outperforming other comparator agents.

这项研究评估了KHP-3757（一种新型的LpxC抑制剂）和比较剂对全球监测计划中最近，地理上不同的铜绿假单胞菌分离物以及分子表征的广谱β-内酰胺酶阳性，金属离子的体外活性。-β-内酰胺酶阳性和大肠菌素抗性菌株。KHP-3757（MIC_{九十○分之五十○}，0.25 / 0.5毫克/升; 97.4％在≤0.5毫克/升的抑制）显示了强的体外基于MIC活动₉₀个值的铜绿假单胞菌菌株包括广谱-β内酰胺酶阳性，金属-β-内酰胺酶阳性和大肠菌素抗性菌株优于其他比较剂。